



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009

AbCRO, Inc

[View the current AbCRO, Inc Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/17664-AbCRO%2C+Inc.html)

(<http://www.bioportfolio.com/bi corporate/17664-AbCRO%2C+Inc.html>)

Contact Details:

P.O. Box 3341

Stamford

Connecticut

6905

United States of America

Tel: (203) 703-2160

Fax:

Email: abcro@abcro.com

AbCRO Inc., founded in 1999, is an American owned and managed Clinical Research Organization (CRO) operating in Southeastern Europe which provides clinical trials services to pharmaceutical and biotechnology companies.

AbCRO has offices in Bulgaria, Romania, Croatia and Serbia, which are the foundation for comprehensive regional coverage. With ready-access to a broad range of patient populations, AbCRO represents a new approach to patient recruitment for clinical research. As a niche provider with a geographic focus, AbCRO offers financial advantages that offset the escalating costs of clinical research.

The co-founders, Dana A. Leff, MBA, and Christa Pleasants Hunter, RN, are on-site managers involved in training staff to Western levels of service and professionalism. Their hands-on management style produces results for AbCRO's clients.

AbCRO's full-time local staff of over 30 professional employees manage site selection, study start-up, all necessary approvals by local Regulatory Authorities, monitoring, and overall study conduct. Taken together, AbCRO's services offer a cost-effective option to meet clients' patient recruitment goals

Press Releases on AbCRO, Inc:

[Frost & Sullivan Identifies](#)

[Focus on Quality](#)

[Management and Adoption of a Full-service Model as Keys](#)

[to the Growth of the](#)

[European CRO Market](#)

12th October, 2009

LONDON, October 12

/PRNewswire/ -- Although cost efficiency is a major factor motivating pharmaceutical and biotechnology firms to outsource research, there is an increased emphasis on expertise and

- [Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Ralcorp Holdings Inc, Aqua America Inc, MetroPCS C](#)
Guru Focus: Nov 16 2009 3:51AM Matching: inc
- [BELLUS Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
PR inside: Nov 16 2009 4:26AM Matching: inc
- [BELLUS Health Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
PR inside: Nov 16 2009 4:26AM Matching: inc
- [J.C. Penney, Disney, Genzyme are big movers](#)
Austin American Statesman: Nov 15 2009 1:20PM Matching: inc
- [UPDATING and REPLACING -- GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Confere](#)
Presentation Master: Nov 15 2009 12:49AM Matching: inc
- [GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Conference Call](#)
Presentation Master: Nov 15 2009 12:48AM Matching: inc
- [J.C. Penney, Disney, Genzyme are big movers](#)
Crescent-News: Nov 15 2009 12:29AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
World Market Media: Nov 14 2009 11:33PM Matching: inc
- [Our Members Know First!! PSGI-'Prime Star Group Introduces Delizia Limited Cigars' Sign Up Today!!](#)
Pharmacy Choice: Nov 14 2009 12:56AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
Review Seeker: Nov 14 2009 9:41AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
RBC Dain Rauscher: Nov 14 2009 4:53AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
Media Workstation: Nov 14 2009 1:40AM Matching: inc
- [Semi-Annual Changes to the NASDAQ Biotechnology Index](#)
DMN Newswire: Nov 14 2009 1:32AM Matching: inc
- [Warning Letters 2009](#)
U.S. Food and Drug Administration: Nov 14 2009 2:40AM Matching: inc
- [UPDATING and REPLACING -- GeoPharma Announces Fiscal Year 2010 Second Quarter Results Release Date and Conference Call](#)
World Market Media: Nov 14 2009 5:12AM Matching: inc

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

